A Phase 1, Open-Label, Single-Arm Study to Assess the Effects of Relugolix Combination Therapy on Ovulation Inhibition in Healthy Women
Latest Information Update: 27 Oct 2020
At a glance
- Drugs Estradiol/norethisterone acetate/relugolix (Primary)
- Indications Pain; Uterine leiomyoma
- Focus Pharmacodynamics
- Sponsors Myovant Sciences
Most Recent Events
- 21 Oct 2020 Results presented in a Myovant Sciences Media Release.
- 21 Oct 2020 According to a Myovant Sciences media release, data presented at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress.
- 06 Jul 2020 According to a Myovant Sciences media release, results from this trial were presented in a virtual poster presentation during the European Society of Human Reproduction and Embryology (ESHRE) virtual 36th Annual Meeting 2020.